Caris Life Sciences, Inc.
CAIAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 5, 2026 | UBS | $38.00(+14%) | $33.22 | StreetInsider | |
| Oct 27, 2026 | BTIG | $38.00(+17%) | $32.45 | TheFly | |
| Sep 9, 2026 | UBS | $28.00(+13%) | $24.82 | TheFly | |
| Aug 7, 2026 | BTIG | $33.00(+65%) | $20.00 | TheFly | |
| Aug 6, 2026 | Evercore ISI | $26.00(+58%) | $16.45 | TheFly | |
| Jul 6, 2026 | Evercore ISI | $25.00(+41%) | $17.71 | TheFly | |
| May 8, 2026 | Robert W. Baird | Catherine Ramsey Schulte | $22.00(+38%) | $15.97 | TheFly |
| May 8, 2026 | BTIG | Mark Massaro | $32.00(+61%) | $19.84 | TheFly |
| Apr 10, 2026 | Piper Sandler | $21.00(+17%) | $17.89 | TheFly | |
| Feb 17, 2026 | Robert W. Baird | $26.00(+26%) | $20.62 | TheFly | |
| Jan 5, 2026 | Evercore ISI | $38.00(+42%) | $26.68 | TheFly | |
| Dec 22, 2025 | Canaccord Genuity | Kyle Mikson | $30.00(+7%) | $27.94 | TheFly |
| Dec 2, 2025 | Canaccord Genuity | $28.00(+7%) | $26.05 | TheFly | |
| Aug 13, 2025 | BTIG | Mark Massaro | $45.00(+29%) | $34.78 | TheFly |
| Jul 13, 2025 | Guggenheim | Subbu Nambi | $32.00(+21%) | $26.51 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Citigroup | maintain | Buy | Nov 6, 2026 |
| TD Cowen | maintain | Buy | Nov 5, 2026 |
| BTIG | maintain | Buy | Nov 5, 2026 |
| BTIG | maintain | Buy | Oct 27, 2026 |
| Canaccord Genuity | maintain | Hold | Oct 19, 2026 |
| JP Morgan | maintain | Overweight | Oct 14, 2026 |
| TD Cowen | maintain | Buy | Oct 13, 2026 |
| Evercore ISI Group | maintain | Outperform | Aug 6, 2026 |
| BTIG | maintain | Buy | Aug 6, 2026 |
| JP Morgan | maintain | Overweight | Aug 5, 2026 |
| Evercore ISI Group | maintain | Outperform | Jul 6, 2026 |
| BTIG | maintain | Buy | Jul 2, 2026 |
| Citigroup | maintain | Buy | May 8, 2026 |
| JP Morgan | maintain | Overweight | May 8, 2026 |
| BTIG | maintain | Buy | May 8, 2026 |
| Evercore ISI Group | maintain | Outperform | Apr 6, 2026 |
| Canaccord Genuity | maintain | Hold | Mar 13, 2026 |
| Evercore ISI Group | maintain | Outperform | Feb 27, 2026 |
| Baird | maintain | Outperform | Feb 27, 2026 |
| BTIG | maintain | Buy | Feb 27, 2026 |
| Canaccord Genuity | maintain | Hold | Dec 22, 2025 |
| Guggenheim | maintain | Buy | Aug 13, 2025 |
| Evercore ISI Group | maintain | Outperform | Aug 13, 2025 |
| Citigroup | maintain | Buy | Aug 13, 2025 |
Earnings History
Next report: Feb 25, 2027 · EPS est. $0.09| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 4, 2026 | $0.05 | $0.03 | $275.4M | $255.4M |
| Aug 5, 2026 | $-0.00 | $0.01 | $263.7M | $238.1M |
| May 7, 2026 | $-0.00 | $-0.02 | $216.2M | $209.4M |
| Feb 26, 2026 | $0.28 | $0.01 | $292.9M | $209.5M |
| Nov 5, 2025 | $0.08 | $-0.08 | $216.8M | $174.1M |
| Aug 12, 2025 | $-0.54 | $-0.21 | $181.4M | $138.0M |
| Jun 9, 2025 | $-0.35 | $-0.22 | $120.9M | $138.0M |
| Nov 5, 2021 | $2.95 | $0.61 | $100.8M | $90.2M |
News
Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call Transcript
Caris Life Sciences NASDAQ: CAI raised its full-year revenue outlook after third-quarter sales rose 27%, as growth in cancer-testing volumes accelerated for a second consecutive quarter. The company also reported lower quarterly profit as it increased spending on its sales force, marketing and new tests.
Caris Life Sciences,?Inc. (CAI) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.08 per share a year ago.
Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total oncology tests Raises 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29% IRVING, Texas, Nov. 4, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quar…
Caris Life Sciences,?Inc. (CAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New campaign connects AI-powered performance insights linking advanced molecular intelligence to help detect cancer in earlier stages IRVING, Texas, Oct. 19, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced the launch of the second commercial in a series promoting Caris Detect™, Caris' multi-cancer early detection (MCED) test, featuring three-time major champion professional golfer, Jordan Spieth. The campaign emphasizes that while modern techno…
IRVING, Texas, Oct. 15, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced it will report third quarter 2026 financial results on Wednesday, November 4, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m.
Eight posters will feature AI-driven approaches to treatment prediction, risk stratification and biomarker discovery advancing precision medicine across multiple cancer types IRVING, Texas, Oct. 14, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced that researchers from Caris and the Caris Precision Oncology Alliance® (Caris POA) will present eight posters at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23…
City Center Advisors LLC acquired a new stake in Caris Life Sciences, Inc. (NASDAQ: CAI) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 18,489 shares of the company's stock, valued at approximately $566,000. Other hedge funds and other institutional investors have also
Caris stock is pulling back after more than doubling in just two months. Wait for the IPO stock to offer a new buy point.
Caris Life Sciences has an already established profiling business that provides revenue and cash flows for its expanding diagnostics portfolio. CAI reuses molecular data and clinical relationships, leveraging them into new tests that I believe should increase their shareholder value in the long run. CAI's Detect broadens its growth potential. However, we still need to see if their cash-pay adoption and marketing expenses pay off as intended.
Caris Life Sciences, Inc. (CAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
New partnership highlights the importance of finding cancer earlier through Caris Detect, a multi-cancer early detection blood test now available nationwide IRVING, Texas, Sept. 8, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced the launch of its new national campaign titled, "Math," featuring the iconic, award-winning actor, producer and director, Kevin Costner.
Seven studies will be presented, including two mini oral presentations and a poster tour presentation IRVING, Texas, Sept. 2, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced that researchers from Caris and the Caris Precision Oncology Alliance® (Caris POA) will present seven studies at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC), taking place September 12-15, 2026, in Seoul, Sou…
Caris Life Sciences (Nasdaq:CAI), the Nasdaq-listed Techbio company, has published a study describing an artificial intelligence (AI) tool designed to help doctors choose first-line treatment for pancreatic cancer. The research, published in npj Precision Oncology, describes the development and validation of the Caris AI Insights model using outcomes from patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Caris AI Insights for pancreatic cancer is proprietary, only available to Caris Life Sciences customers and not achievable through small panels IRVING, Texas, Aug. 27, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced the publication of a study in npj Precision Oncology describing the development and validation of an AI-driven approach to optimize first-line treatment selection in pancreatic cancer, advancing a more personalized care path for one…